Sacituzumab tirumotecan
Kelun-Biotech · Merck & Co. · SKB264 · MK-2870
FollowEvery change as it happens, and a Monday email
Trials
48 active
50 in total · 29 in the EU
What this is
- How it works
- TROP2-targeted antibody-drug conjugate
- How it’s given
- “SKB264 :5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles:…”In the company’s words, NCT05347134 on ClinicalTrials.gov
- Tested for
- Non-small Cell Lung Cancer (9 trials), Non-small Cell Lung Cancer (NSCLC) (3 trials), Triple Negative Breast Cancer (2 trials), Metastatic Breast Cancer (2 trials), Breast Neoplasms (2 trials), Endometrial Cancer (2 trials), Cervical Cancer (2 trials), NSCLC (2 trials) and 32 more
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care”In the company’s words, NCT05347134 on ClinicalTrials.gov
- Other names
- SKB264 · MK-2870 · sac-TMT
Other drugs for Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up12
- NovPhase 3 trial completes · ClinicalTrials.gov
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
- DecPhase 3 trial completes · ClinicalTrials.gov
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 10 May 2027Phase 3 trial completes · ClinicalTrials.gov
- May 2027Phase 3 trial completes · ClinicalTrials.gov
- 11 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 11 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovCompletion date moved: 2026-06-30 to 2026-08-31 · ClinicalTrials.gov NCT05816252
Trials50
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Nov 2023 | SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | |
| Phase 3Active, not recruiting | 11 Jul 2024 | A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | |
| Phase 3Active, not recruiting | 19 Oct 2026 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | |
| Phase 3Active, not recruiting | Nov 2026 | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |
| Phase 3Active, not recruiting | Dec 2026 | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | |
| Phase 3Recruiting | 31 Dec 2026 | Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | |
| Phase 3Active, not recruiting | Apr 2027 | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | |
| Phase 3Active, not recruiting | 10 May 2027 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | |
| Phase 3Active, not recruiting | May 2027 | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | |
| Phase 3Recruiting | 11 Jul 2027 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | |
| Phase 3Recruiting | Jul 2027 | A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy | |
| Phase 3Active, not recruiting | 10 Jan 2028 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) | |
| Phase 3Recruiting | 25 Jan 2028 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | |
| Phase 3Active, not recruiting | 15 Jun 2028 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | |
| Phase 3Active, not recruiting | 17 Aug 2028 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | |
| Phase 3Recruiting | 12 Jan 2029 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | |
| Phase 3Recruiting | 27 Apr 2029 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | |
| Phase 3Recruiting | 27 Jul 2029 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | |
| Phase 3Recruiting | 18 May 2030 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | |
| Phase 3Recruiting | 16 Dec 2030 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | |
| Phase 3Recruiting | 29 Oct 2031 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | |
| Phase 3Recruiting | 17 Nov 2031 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) | |
| Phase 3Recruiting | 24 May 2032 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | |
| Phase 3Recruiting | 25 Feb 2033 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | |
| Phase 3Recruiting | 23 Mar 2033 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | |
| Phase 3Recruiting | 21 Feb 2034 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | |
| Phase 2Active, not recruiting | 31 Aug 2026 | A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | |
| Phase 2Recruiting | Aug 2026 | SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | |
| Phase 2Active, not recruiting | 30 Dec 2026 | SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors | |
| Phase 2Recruiting | 31 Aug 2027 | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | |
| Phase 2Not yet recruiting | 30 Dec 2027 | A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure | |
| Phase 2Active, not recruiting | Jan 2028 | Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC | |
| Phase 2Recruiting | Apr 2028 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | |
| Phase 2Recruiting | Aug 2028 | SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer | |
| Phase 2Recruiting | 15 Nov 2029 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | |
| Phase 2Recruiting | 30 Sep 2031 | A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) | |
| Phase 2Active, not recruiting | 6 Feb 2032 | Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) | |
| Phase 1/2Recruiting | 11 Jun 2027 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | |
| Phase 1/2Active, not recruiting | 31 Mar 2028 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | |
| Phase 1/2Recruiting | 9 May 2028 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | |
| Phase 1/2Recruiting | 17 Aug 2029 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | |
| Phase 1/2Recruiting | 12 Sep 2029 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | |
| Phase 1/2Recruiting | 16 Oct 2029 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | |
| Phase 1/2Recruiting | Dec 2029 | SKB118 Injection in Advanced Solid Tumors | |
| Phase 1/2Recruiting | 4 Jan 2032 | Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) | |
| Phase 1/2Not yet recruiting | 29 Jun 2032 | MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) | |
| Phase 1Active, not recruiting | 31 Dec 2027 | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | |
| Phase 2Completed | 31 Jul 2026 | SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer | |
| Phase 1/2Completed | 30 Sep 2026 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | |
| Phase 2Authorised | not given | RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026